Modus Therapeutics Holding AB

As of June 30, 2026, Modus Therapeutics Holding AB carries a market capitalization of 55.91M, placing it among publicly traded companies globally. Its enterprise value stands at 43.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Modus Therapeutics Holding AB has 148.70M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Modus Therapeutics Holding AB maintains a current ratio of 4.37, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is - -, indicating a certain level of leverage, while an interest coverage ratio of -150.70 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -210.68, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Modus Therapeutics Holding AB's stock has declined approximately 57.14% over the past 52 weeks. The 50-day moving average sits at 0.38, while the 200-day moving average is 0.37.

Over the twelve months ended June 30, 2026, Modus Therapeutics Holding AB generated - - in revenue and converted that into -17.59M in net income, yielding earnings per share of -0.16. EBITDA reached -17.48M, while operating income came in at -17.48M.

As of June 30, 2026, Modus Therapeutics Holding AB holds 12.49M in cash and equivalents against - - in total debt, resulting in a net debt position of -12.49M. Total book value stands at 10.24M, with working capital of 10.24M providing operational flexibility.

Modus Therapeutics Holding AB produced -18.57M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -45.10: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -52.16, meaning Modus Therapeutics Holding AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Modus Therapeutics Holding AB's most recent stock split took place on August 7, 2025 with a 41:104 split ratio.

As of June 30, 2026, Modus Therapeutics Holding AB has an Altman Z-Score of -30.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.